Evidence map›Paper›PMID 39363900›Full record

ArticleFrontiers in endocrinology2024

A comprehensive prediction model for central lymph node metastasis in papillary thyroid carcinoma with Hashimoto's thyroiditis: BRAF may not be a valuable predictor.

Yanwei Chen, Shuangshuang Zhao, Zheng Zhang, Zheming Chen, Bingxin Jiang, Maohui An, Mengyuan Shang, Xincai Wu, Xin Zhang, Baoding Chen

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yanwei ChenDepartment of Medical Ultrasound, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Shuangshuang ZhaoDepartment of Medical Ultrasound, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Zheng ZhangDepartment of Medical Ultrasound, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Zheming ChenDepartment of Medical Ultrasound, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Bingxin JiangDepartment of Medical Ultrasound, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Maohui AnDepartment of Medical Ultrasound, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Mengyuan ShangDepartment of Medical Ultrasound, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Xincai WuDepartment of Medical Ultrasound, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Xin ZhangDepartment of Medical Ultrasound, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Baoding ChenDepartment of Medical Ultrasound, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Papillary thyroid carcinoma (PTC) frequently coexists with Hashimoto's thyroiditis (HT), which poses challenges in detecting central lymph node metastasis (CLNM) and determining optimal surgical management. Our study aimed to identify the independent predictors for CLNM in PTC patients with HT and develop a comprehensive prediction model for individualized clinical decision-making. Patients and methods: In this retrospective study, a total of 242 consecutive PTC patients who underwent thyroid surgery and central lymph node dissection between February 2019 and December 2021 were included. 129 patients with HT were enrolled as the case group and 113 patients without HT as control. The results of patients' general information, laboratory examination, ultrasound features, pathological evaluation, and BRAF mutation were collected. Multivariate logistic regression analysis was used to identify independent predictors, and the prediction model and nomogram were developed for PTC patients with HT. The performance of the model was assessed using the receiver operating characteristic curve, calibration curve, decision curve analysis, and clinical impact curve. In addition, the impact of the factor BRAF mutation was further evaluated. Results: Multivariate analysis revealed that gender (OR = 8.341, P = 0.013, 95% CI: 1.572, 44.266), maximum diameter (OR = 0.316, P = 0.029, 95% CI: 0.113, 0.888), multifocality (OR = 3.238, P = 0.010, 95% CI: 1.319, 7.948), margin (OR = 2.750, P = 0.046, 95% CI: 1.020, 7.416), and thyrotropin receptor antibody (TR-Ab) (OR = 0.054, P = 0.003, 95% CI: 0.008, 0.374) were identified as independent predictors for CLNM in PTC patients with HT. The area under the curve of the model was 0.82, with accuracy, sensitivity, and specificity of 77.5%, 80.3% and 75.0%, respectively. Meanwhile, the model showed satisfactory performance in the internal validation. Moreover, the results revealed that BRAF mutation cannot further improve the efficacy of the prediction model. Conclusion: Male, maximum diameter > 10mm, multifocal tumors, irregular margin, and lower TR-Ab level have significant predictive value for CLNM in PTC patients with HT. Meanwhile, BRAF mutation may not have a valuable predictive role for CLNM in these cases. The nomogram constructed offers a convenient and valuable tool for clinicians to determine surgical decision and prognostication for patients.

Indexed as

Hashimoto DiseaseLymphatic MetastasisProto-Oncogene Proteins B-rafThyroid Cancer, PapillaryThyroid NeoplasmsAdultFemaleHumansMaleMiddle AgedMutationNomogramsPrognosisRetrospective StudiesBRAF protein, humanProto-Oncogene Proteins B-rafBRAF mutationcentral lymph node metastasisHashimoto’s thyroiditisnomogrampapillary thyroid carcinomaprediction model

Identifiers

PMID39363900
PMCPMC11446765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.